Hiroshi Yamamoto

Nagasaki, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study).

Journal: Drug discoveries & therapeutics
Published: April 26, 2026

Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease.

Early longitudinal proteomic changes during sirolimus therapy in tocilizumab-refractory idiopathic multicentric Castleman disease.

Journal: Rheumatology (Oxford, England)
Published: March 30, 2026

A phase II investigator-initiated, continuation trial of 5-aminolevulinic acid hydrochloride/sodium ferrous citrate (5-ALA-HCl/SFC) for patients with adult-onset Still's disease (AOSD) refractory to glucocorticoids.

A phase II investigator-initiated, continuation trial of 5-aminolevulinic acid hydrochloride/sodium ferrous citrate (5-ALA-HCl/SFC) for patients with adult-onset Still's disease (AOSD) refractory to glucocorticoids.

Journal: Drug discoveries & therapeutics
Published: December 10, 2025

A Placebo-Controlled Exploratory Trial of Sirolimus for Tocilizumab-Resistant Idiopathic Multicentric Castleman Disease: Early Termination and Long-Term Extension Results Based on Descriptive Results From Two Patients.

A Placebo-Controlled Exploratory Trial of Sirolimus for Tocilizumab-Resistant Idiopathic Multicentric Castleman Disease: Early Termination and Long-Term Extension Results Based on Descriptive Results From Two Patients.

Journal: Cureus
Published: December 01, 2025

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study).

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study).

Journal: Frontiers in medicine
Published: October 06, 2025

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.

Switching from originator infliximab to biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission (the IFX-SIRIUS study I): An interventional, multicenter, open-label, single-arm clinical trial with clinical, ultrasound and biomarker assessments.

Journal: Drug discoveries & therapeutics
Published: August 24, 2025

A Phase-II Investigator-Initiated Randomized, Double-Blind, Parallel-Group Clinical Trial of 5-Aminolevulinic Acid Hydrochloride/Sodium Ferrous Citrate (5-ALA-HCl/SFC) for Patients With Adult-Onset Still's Disease (AOSD) Refractory to Corticosteroids.

A Phase-II Investigator-Initiated Randomized, Double-Blind, Parallel-Group Clinical Trial of 5-Aminolevulinic Acid Hydrochloride/Sodium Ferrous Citrate (5-ALA-HCl/SFC) for Patients With Adult-Onset Still's Disease (AOSD) Refractory to Corticosteroids.

Journal: Cureus
Published: August 17, 2025

Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab.

Discontinuation of biosimilar infliximab in Japanese patients with rheumatoid arthritis achieving sustained clinical remission or low disease activity during the IFX-SIRIUS STUDY I (the IFX-SIRIUS STUDY II): A clinical, ultrasound, and biomarker-based effectiveness after discontinuation and reinitiation of biosimilar infliximab.

Journal: Global health & medicine
Published: May 16, 2025

Efficacy of etanercept biosimilar switching from etanercept reference product, using ultrasound and clinical data in outcomes of real world therapy (ESCORT-NGSK Study).

Efficacy of etanercept biosimilar switching from etanercept reference product, using ultrasound and clinical data in outcomes of real world therapy (ESCORT-NGSK Study).

Journal: Drug discoveries & therapeutics
Published: February 26, 2025

Effectiveness of Etanercept Biosimilar Initiating for Etanercept-Naive Patients, Using Ultrasound, Clinical, and Biomarker Assessments in Outcomes of Real-World Therapy (ENPORT-NGSK Study): An Interventional, Multicenter, Open-Label, Single-Arm Clinical Trial.

Effectiveness of Etanercept Biosimilar Initiating for Etanercept-Naive Patients, Using Ultrasound, Clinical, and Biomarker Assessments in Outcomes of Real-World Therapy (ENPORT-NGSK Study): An Interventional, Multicenter, Open-Label, Single-Arm Clinical Trial.

Journal: Journal of clinical medicine
Published: January 30, 2025

Investigating the impact of tocilizumab on serum cytokines concentrations in Japanese FMF patients: a sub-analysis of the NUH01FMF study.

Investigating the impact of tocilizumab on serum cytokines concentrations in Japanese FMF patients: a sub-analysis of the NUH01FMF study.

Journal: Immunological medicine
Published: October 23, 2024

A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.

A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.

Journal: Microbiology spectrum
Published: May 04, 2023
Showing 1-12 of 28

Last Updated: 09/26/2026